Familial hypercholesterolaemia: PCSK9 inhibitors are coming

The Lancet

Volumn 385, Issue 9965, 2015, Pages 307-310

  Santos, Raul D ^a   Watts, Gerald F ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; BOCOCIZUMAB; C REACTIVE PROTEIN; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

AORTA SUPRAVALVULAR STENOSIS; APHERESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HEREDITY; HUMAN; NOTE; PATIENT RISK; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; UPREGULATION; XANTHOMA; ANTAGONISTS AND INHIBITORS; FEMALE; HYPERLIPOPROTEINEMIA TYPE II; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84921528143     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61702-5     Document Type: Note

References (23)

1. BG Nordestgaard, MJ Chapman, SE Humphries et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 3490
2. M Benn, GF Watts, A Tybjaerg-Hansen, BG Nordestgaard Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication J Clin Endocrinol Metab 97 2012 3956 3964
3. B Sjouke, DM Kusters, I Kindt et al. Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome Eur Heart J 2014 10.1093/eurheartj/ehu058 published online Feb 28.
4. FJ Raal, RD Santos Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment Atherosclerosis 223 2012 262 268
5. R Alonso, E Andres, N Mata for the SAFEHEART Investigators Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation J Am Coll Cardiol 63 2014 1982 1989
6. J Versmissen, DM Oosterveer, M Yazdanpanah et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 2008 a2423
7. JD Horton, JC Cohen, HH Hobbs PCSK9: a convertase that coordinates LDL catabolism J Lipid Res 50 suppl 2009 S172 S177
8. GF Watts, S Gidding, AS Wierzbicki et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation Int J Cardiol 171 2014 309 325
9. FJ Raal, RD Santos, DJ Blom et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
10. M Cuchel, EA Meagher, H du Toit Theron et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
11. RD Santos Lipid-lowering treatment for homozygous familial hypercholesterolaemia Lancet 381 2013 1182
12. PM Ridker LDL cholesterol: controversies and future therapeutic directions Lancet 384 2014 607 617
13. EA Stein, D Gipe, J Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
14. F Raal, R Scott, R Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2411
15. EA Stein, N Honarpour, SM Wasserman, F Xu, R Scott, FJ Raal Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
16. DJ Rader, W Cain, K Ikewaki et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate J Clin Invest 93 1994 2758 2763
17. FJ Raal, N Honarpour, DJ Blom for the TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 2014 published online Oct 2. http://dx.doi.org/10.1016/S0140-6736(14)61374-X
18. FJ Raal, EA Stein, R Dufour for the RUTHERFORD-2 Investigators PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 2014 published online Oct 2. http://dx.doi.org/10.1016/S0140-6736(14)61399-4
19. A Varbo, M Benn, A Tybjaerg-Hansen, BG Nordestgaard Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein causes ischemic heart disease without inflammation Circulation 128 2013 1298 1309
20. M Seed, DJ Betteridge, J Cooper et al. Normal levels of inflammatory markers in treated patients with familial hypercholesterolemia: a cross-sectional study JRSM Cardiovasc Dis 1 2012 1 9
21. DJ Blom, T Hala, M Bolognese et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
22. E Stroes, D Colquhoun, D Sullivan et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
23. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681